Related references
Note: Only part of the references are listed.Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation
M. Judith Peterschmitt et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Venglustat in adult Gaucher disease type 3: Preliminary safety, pharmacology, and exploratory efficacy from a phase 2 trial in combination with imiglucerase (LEAP)
Raphael Schiffmann et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Sphingolipids and their metabolism in physiology and disease
Yusuf A. Hannun et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Genetics and Therapies for GM2 Gangliosidosis
Maria Begoila Cachon-Gonzalez et al.
CURRENT GENE THERAPY (2018)
The role of glucocerebrosidase in Parkinson disease pathogenesis
Matthew E. Gegg et al.
FEBS JOURNAL (2018)
Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease
James A. Shayman
SEMINARS IN NEPHROLOGY (2018)
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A
Jialin Mao et al.
DRUG METABOLISM REVIEWS (2017)
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Jerome Stirnemann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease
Elma Aflaki et al.
NEURON (2017)
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
John Marshall et al.
MOLECULAR THERAPY (2016)
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease
Karen M. Ashe et al.
MOLECULAR MEDICINE (2015)
A novel approach for quantitation of glucosylceramide in human dried blood spot using LC-MS/MS
Allena Ji Ji et al.
BIOANALYSIS (2015)
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects
Sreeneeranj Kasichayanula et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease
Thomas A. Natoli et al.
HUMAN MOLECULAR GENETICS (2012)
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1
Elena Lukina et al.
BLOOD (2010)
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models
Thomas A. Natoli et al.
NATURE MEDICINE (2010)
Sphingolipid metabolism diseases
Thomas Kolter et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2006)
Share Paper
